Subscribe To
Allergy therapeutics peanut vaccine candidate negotiates its early clinical hurdle
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced a significant milestone in its innovative peanut allergy treatment with the successful co...
April 19, 2023, 2:41 am
Vaxcyte (pcvx) up on pneumococcal conjugate vaccine data
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine ...
April 18, 2023, 2:28 pm
Gamida cell shares jump on fda recognition of allogeneic cell therapy
Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug ...
April 18, 2023, 12:13 pm
Genprex encouraged by latest reports on novel tumor suppressor
Genprex, Inc. (NASDAQ:GNPX) said independent researchers have reported that the tumor suppression gene used in its lead drug ...
April 18, 2023, 11:06 am
Moderna (mrna), merck's cancer jab delays melanoma recurrence
Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candid...
April 17, 2023, 12:56 pm
Roivant sciences shares spike on merck-prometheus biosciences deal
Roivant Sciences shares took off on the news that Merck is acquiring Prometheus Biosciences in a $10.8 billion deal as investors placed their bets o...
April 17, 2023, 12:23 pm
Biovie to present phase 2 trial data abstracts at 2023 american academy of neurology annual meeting
BioVie announced that data abstracts from its Phase 2 trials evaluating NE3107 in degenerative dementias and Parkinson's disease will be presented at ...
April 17, 2023, 12:01 pm
Prometheus (rxdx) stock surges 70% on buyout offer from merck
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candid...
April 17, 2023, 10:41 am
2 growth stocks that jumped 42% and 58% last week: can they still climb higher?
The week that ended April 14 was a good one for markets overall and a great one for two stocks in the healthcare sector. Sana Biotechnology jumped 58%...
April 17, 2023, 6:17 am
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...
April 16, 2023, 9:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fid...
April 16, 2023, 9:00 pm
Frontier medicines presents new preclinical data on its development candidate, fmc-376, a dual krasg12c inhibitor, at the 2023 aacr annual meeting
-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and over...
April 16, 2023, 7:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm
Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f
SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...
April 16, 2023, 5:00 pm